https://scholars.lib.ntu.edu.tw/handle/123456789/531741
標題: | Acarbose use and liver injury in diabetic patients with severe renal insufficiency and hepatic diseases: A propensity score-matched cohort study | 作者: | CHIA-TER CHAO Wang J. JENQ-WEN HUANG KUO-LIONG CHIEN |
公開日期: | 2018 | 出版社: | Frontiers Media S.A. | 卷: | 9 | 期: | AUG | 起(迄)頁: | 860 | 來源出版物: | Frontiers in Pharmacology | 摘要: | Background: Acarbose has been deemed contraindicated in diabetic patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD), but such use is not uncommon. We tested whether this concept hold true in this population with different background hepatic diseases. Methods: All incident diabetic patients (n = 2,036,531) with stage 5 CKD/ESRD were enrolled from Taiwan between 2017 and 2013 and divided into those without chronic liver disease (CLD), with CLD but without cirrhosis, and those with cirrhosis. Among each group, acarbose users, defined as cumulative use > 30 days within the preceding year, were propensity-score matched 1:2 to non-users. Our main outcome was the development of liver injury events during follow-up. Results: Acarbose users did not exhibit an increased incidence of liver injury during follow-up compared to non-users (hazard ratio and 95% confidence interval, 1.04 [0.88-1.25], 0.97 [0.61-1.56], and 0.71 [0.33-1.54] among those without CLD, with CLD but without cirrhosis, and those with cirrhosis, respectively), after adjusting for demographic profiles, comorbidities, potentially hepatotoxic medication use, and diabetic severity. Conclusions: The incidence of liver injury did not increase significantly among diabetic acarbose users with severe renal insufficiency than non-users, regardless of the presence or absence of chronic liver disease. Our findings support the renaissance of acarbose as a useful adjunct in diabetic patients with stage 5 and 5D chronic kidney disease. ? 2018 Chao, Wang, Huang and Chien. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054932409&doi=10.3389%2ffphar.2018.00860&partnerID=40&md5=3cd0b7286d15e18deb0df0cf9b981258 https://scholars.lib.ntu.edu.tw/handle/123456789/531741 |
ISSN: | 1663-9812 | DOI: | 10.3389/fphar.2018.00860 | SDG/關鍵字: | acarbose; adult; aged; Article; chronic liver disease; clinical outcome; cohort analysis; comorbidity; confidence interval; controlled study; demography; diabetic patient; drug use; end stage renal disease; female; follow up; hazard ratio; human; incidence; liver cirrhosis; liver injury; liver toxicity; major clinical study; male; non insulin dependent diabetes mellitus; population research; propensity score; severe renal impairment; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。